Bellik Lydia, Dragoni Stefania, Pessina Federica, Sanz Elisenda, Unzeta Mercedes, Valoti Massimo
Dipartimento di Neuroscienze, Università di Siena, Italy.
Acta Biochim Pol. 2010;57(2):235-9. Epub 2010 Jun 9.
The novel MAO-B inhibitor PF9601N, its cytochrome P450-dependent metabolite FA72 and l-deprenyl were studied as potential peroxynitrite (ONOO(-)) scavengers and nitric oxide synthase (NOS) inhibitors. The scavenging activity of these compounds was evaluated by measuring the oxygen consumption through peroxynitrite-mediated oxidation of both linoleic acid and brain homogenate. FA72, PF9601N and l-deprenyl caused a concentration-dependent inhibition of ONOO(-)-induced linoleic acid oxidation with an IC(50) value of 60.2 microM, 82.8 microM and 235.8 microM, respectively. FA72 was the most potent also in inhibiting ONOO(-)-induced brain homogenate oxidation with an IC(50) value of 99.4 microM, while PF9601N and l-deprenyl resulted weaker inhibitors in the same experimental model, showing an IC(50) value of 164.8 and 112.0 microM, respectively. Furthermore, both the novel MAO-B inhibitor as well as its metabolite were able to strongly inhibit rat brain neuronal NOS (IC(50) of 183 microM and 192 microM, respectively), while l-deprenyl at the highest concentration used (3 mM), caused only a slight decrease of the enzyme activity. Moreover, inducible NOS was strongly inhibited by FA72 only. All these results suggest that PF9601N could be a promising therapeutic agent in neurodegenerative disorders such as Parkinson's disease.
新型单胺氧化酶B(MAO-B)抑制剂PF9601N、其细胞色素P450依赖性代谢产物FA72和左旋司来吉兰被作为潜在的过氧亚硝酸盐(ONOO(-))清除剂和一氧化氮合酶(NOS)抑制剂进行研究。通过测量过氧亚硝酸盐介导的亚油酸和脑匀浆氧化过程中的耗氧量,评估了这些化合物的清除活性。FA72、PF9601N和左旋司来吉兰对ONOO(-)诱导的亚油酸氧化产生浓度依赖性抑制,IC(50)值分别为60.2 microM、82.8 microM和235.8 microM。在抑制ONOO(-)诱导的脑匀浆氧化方面,FA72也是最有效的,IC(50)值为99.4 microM,而在同一实验模型中,PF9601N和左旋司来吉兰的抑制作用较弱,IC(50)值分别为164.8 microM和112.0 microM。此外,新型MAO-B抑制剂及其代谢产物均能强烈抑制大鼠脑神经元NOS(IC(50)分别为183 microM和192 microM),而左旋司来吉兰在所用的最高浓度(3 mM)下,仅使酶活性略有下降。此外,仅FA72能强烈抑制诱导型NOS。所有这些结果表明,PF9601N可能是帕金森病等神经退行性疾病一种有前景的治疗药物。